Journal of Anesthesia

, Volume 32, Issue 2, pp 236–243 | Cite as

Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics

  • Akihiro Kanaya
  • Toshihiro Sato
  • Nobuo Fuse
  • Hiroaki Yamaguchi
  • Nariyasu Mano
  • Masanori Yamauchi
Original Article



Propofol is one of the most widely used fast-acting intravenously administered anesthetics. However, although large inter-individual differences in dose requirements and recovery time have been observed, there are few previous studies in which the association between several potential covariates, including genetic factors such as the UGT1A9 and CYP2B6 genotypes, and propofol pharmacokinetics was simultaneously examined. This study aimed to identify factors determining propofol pharmacokinetics.


Eighty-three patients were enrolled, and their blood samples were collected 1, 5, 10, and 15 min after administering a single intravenous bolus of propofol at a dose of 2.0 ml/kg to measure propofol plasma concentration. Area under the time–plasma concentration curve from zero up to the last measurable time point (AUC15min) was determined from the concentration data. The inter-individual variability of the propofol pharmacokinetics was evaluated by investigating relationships between AUC15min and genotype of UGT1A9 and CYP2B6; clinical factors, such as age, sex, body mass index (BMI), and preoperative hematological examination; and hemodynamic variables measured by a pulse dye densitogram analyzer. The Spearman rank correlation coefficient and the Mann–Whitney U test were used for the statistical analysis of continuous and categorical values, respectively. Subsequently, clinical factors that had p values of < 0.05 in the univariate analysis were examined in a multivariate analysis using multiple linear regression analysis.


Age, BMI, indocyanine green disappearance ratio (K-ICG), hepatic blood flow (HBF), preoperative hemoglobin level, and sex were correlated with AUC15min (p < 0.05) in univariate analysis. Multivariate analysis performed to adjust for age, BMI, K-ICG, HBF, preoperative hemoglobin level, and sex revealed only BMI as an independent factor associated with AUC15min.


This study demonstrated that BMI influences propofol pharmacokinetics after its administration as a single intravenous injection, while UGT1A9 and CYP2B6 SNPs, other clinical factors, and hemodynamic variables do not. These results suggest that BMI is an independent factor associated with propofol pharmacokinetics in several potential covariates.

Clinical trials registration number

University Hospital Medical Information Network (UMIN000022948).


Propofol Single-nucleotide polymorphism UGT1A9 CYP2B6 Body mass index Pharmacokinetics 



The accomplishment of this dissertation is the joint efforts of all colleagues in Tohoku University School of Medicine and Tohoku Medical Megabank Organization. First, we would like to acknowledge the expert assistance of Ms. Masae Kimura, Department of Integrative Genomics, Tohoku Medical Megabank Organization, who helped with the genomic analyses. Second, workmates in the Department of Anesthesiology and Perioperative Medicine, Tohoku University School of Medicine have great help in conducting this study based on our protocol.


This study was funded by the Department of Anesthesiology and Perioperative Medicine Tohoku University School of Medicine, Sendai Japan.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Glen JB, Hunter SC. Pharmacology of an emulsion formulation of ICI 35 868. Br J Anaesth. 1984;56:617–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Iohom G, Ni Chonghaile M, O’Brien JK, Cunningham AJ, Fitzgerald DF, Shields DC. An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. Eur J Anaesthesiol. 2007;24:912–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Choong E, Loryan I, Lindqvist M, Nordling A, el Bouazzaoui S, van Schaik RH, Johansson I, Jakobsson J, Ingelman-Sundberg M. Sex difference in formation of propofol metabolites: a replication study. Basic Clin Pharmacol Toxicol. 2013;113:126–31.CrossRefPubMedGoogle Scholar
  4. 4.
    Mastrogianni O, Gbandi E, Orphanidis A, Raikos N, Goutziomitrou E, Kolibianakis EM, Tarlatzis BC, Goulas A. Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from Northern Greece. Drug Metab Pharmacokinet. 2014;29:215–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Hoymork SC, Raeder J, Grimsmo B, Steen PA. Bispectral index, serum drug concentrations and emergence associated with individually adjusted target-controlled infusions of remifentanil and propofol for laparoscopic surgery. Br J Anaesth. 2003;91:773–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Hoymork SC, Raeder J. Why do women wake up faster than men from propofol anaesthesia? Br J Anaesth. 2005;95:627–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Gan TJ, Glass PS, Sigl J, Sebel P, Payne F, Rosow C, Embree P. Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men. Anesthesiology. 1999;90:1283–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Tachibana N, Niiyama Y, Yamakage M. Evaluation of bias in predicted and measured propofol concentrations during target-controlled infusions in obese Japanese patients: an open-label comparative study. Eur J Anaesthesiol. 2014;31:701–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Hiraoka H, Yamamoto K, Miyoshi S, Morita T, Nakamura K, Kadoi Y, Kunimoto F, Horiuchi R. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol. 2005;60:176–82.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yufune S, Takamatsu I, Masui K, Kazama T. Effect of remifentanil on plasma propofol concentration and bispectral index during propofol anaesthesia. Br J Anaesth. 2011;106:208–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics. 2004;14:501–15.CrossRefPubMedGoogle Scholar
  12. 12.
    Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001;94:110–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Mikstacki A, Zakerska-Banaszak O, Skrzypczak-Zielinska M, Tamowicz B, Prendecki M, Dorszewska J, Molinska-Glura M, Waszak M, Slomski R. The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia. J Appl Genet. 2017;58:213–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Sawada J. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos. 2009;37:272–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos. 2006;34:1220–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, Zanger UM. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genom. 2005;15:861–73.CrossRefGoogle Scholar
  17. 17.
    Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH, Jakobsson J, Ingelman-Sundberg M. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Eur J Clin Pharmacol. 2012;68:397–406.CrossRefPubMedGoogle Scholar
  19. 19.
    Miyakawa H, Tateda T, Kobayashi Y, Yokozuka M, Kumai T, Inoue S. Effect of CYP2B6 and UGT1A9 genotypes on difference in predicted and measured propofol concentration after propofol anesthesia. J St Marianna Univ. 2016;44:117–27 (in Japanese).Google Scholar
  20. 20.
    Itakura S, Masui K, Kazama T. Rapid infusion of hydroxyethyl starch 70/0.5 but not Acetate Ringer’s solution decreases the plasma concentration of propofol during target-controlled infusion. Anesthesiology. 2016;125:304–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Kansaku F, Kumai T, Sasaki K, Yokozuka M, Shimizu M, Tateda T, Murayama N, Kobayashi S, Yamazaki H. Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age. Drug Metab Pharmacokinet. 2011;26:532–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Yonekura H, Murayama N, Yamazaki H, Sobue K. A case of delayed emergence after propofol anesthesia: genetic analysis. A A Case Rep. 2016;7:243–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18:377–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo WS. Pharmacokinetics of propofol (diprivan) in elderly patients. Br J Anaesth. 1988;60:146–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Cortinez LI, De la Fuente N, Eleveld DJ, Oliveros A, Crovari F, Sepulveda P, Ibacache M, Solari S. Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. Anesth Analg. 2014;119:302–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg. 2006;16:773–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Vricella LK, Louis JM, Chien E, Mercer BM. Blood volume determination in obese and normal-weight gravidas: the hydroxyethyl starch method. Am J Obstet Gynecol. 2015;213:408.e1–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, Mizugaki M. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol. 2002;58:417–21.CrossRefPubMedGoogle Scholar
  30. 30.
    Maeda H, Hazama S, Shavkat A, Okamoto K, Oba K, Sakamoto J, Takahashi K, Oka M, Nakamura D, Tsunedomi R, Okayama N, Mishima H, Kobayashi M. Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations. Mol Diagn Ther. 2014;18:333–42.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Yan W, Wang YW, Yang FF, Wang M, Zhang XQ, Dong J, Chen E, Yang J. Differences in frequencies of UGT1A9, 1A7, and 1A1 genetic polymorphisms in Chinese Tibetan versus Han Chinese populations. Genet Mol Res. 2013;12:6454–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Eleveld DJ, Proost JH, Cortínez LI, Absalom AR, Struys MM. A general purpose pharmacokinetic model for propofol. Anesth Analg. 2014;118:1221–37.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2018

Authors and Affiliations

  • Akihiro Kanaya
    • 1
  • Toshihiro Sato
    • 2
  • Nobuo Fuse
    • 3
  • Hiroaki Yamaguchi
    • 2
  • Nariyasu Mano
    • 2
  • Masanori Yamauchi
    • 1
  1. 1.Department of Anesthesiology and Perioperative MedicineTohoku University School of MedicineSendaiJapan
  2. 2.Department of Pharmaceutical SciencesTohoku University HospitalSendaiJapan
  3. 3.Department of Integrative GenomicsTohoku Medical Megabank OrganizationSendaiJapan

Personalised recommendations